Negative Patient Care Perceptions Linked to Increased Number of Pre-diagnostic Consultations
the Cancer Therapy Advisor take:
There is a negative association between multiple pre-referral consultations with a general practitioner and the patient experience of subsequent cancer care, according to an article published online in the European Journal of Cancer Care.
The study included data from 73,462 respondents to two English Cancer Patient Experience Surveys. The authors evaluated the likelihood of patients reporting negative experiences of subsequent care after three or more (3+) pre-referral consultations compared to one or two consultations.
Results showed a strong correlation (P<0.01 for all) between patients with 3+ pre-referral consultations and perceived worse care experiences (for 10/12 questions), compared to those with 1-2 consultations ranging from 1.10 to 1.68 (95% CI: 1.03, 1.17 vs. 1.60-1.77, respectively).
In other words, patients with 3+ consultations had a +1.8% to +10.6% greater percentage of reporting a negative subsequent care experience than those with 1-2 visits.
The associations were reported to be stronger when related to primary care as opposed to hospital care, and for evaluation than report items.
Furthermore, a “dose-response” relationship was found after considering 1, 2, 3-4, and 5+ pre-referral consultations separately.
There is a negative association between multiple pre-referral consultations with a general practitioner and the patient experience.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- JAK1/2 Inhibition in Myelofibrosis Linked to Increased Risk for Aggressive B-Cell Lymphomas
- Managing Chemotherapy- and Radiation Therapy-Induced Nausea and Vomiting
- Can Oncolytic Viruses Improve Immunotherapies?
- Coffee and Cancer
- Upfront Next-Generation Sequencing Is Faster, More Cost Effective in Metastatic NSCLC
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer
- Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy
- Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer
- Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling